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ABSTRACT 
Rationale: Vascular progenitor cells (VPCs) play key roles in physiological and pathological 
vascular remodelling, a process that is crucial for the regeneration of acellular biodegradable 
scaffolds engineered as vital strategies against the limited availability of healthy autologous 
vessels for bypass grafting. Therefore, understanding the mechanisms driving VPCs 
recruitment and differentiation could help the development of new strategies to improve 
Tissue-Engineered Vessel Grafts (TEVGs) and design drug-targeted therapy for vessel 
regeneration.  
Objective: In this study we sought to investigate the role of Dickkopf-3 (Dkk3), recently 
identified as a cytokine promotor of endothelial repair and smooth muscle cell differentiation, 
on VPC cell migration and vascular regeneration and to identify its functional receptor that 
remains unknown. 
Methods and Results: Vascular stem/progenitor cells were isolated from murine aortic 
adventitia and selected for the Stem cell antigen-1 (Sca-1) marker. Dkk3 induced the 
chemotaxis of Sca-1+ cells in vitro in transwell and wound healing assays, and ex vivo in the 
aortic ring assay. Functional studies to identify Dkk3 receptor revealed that overexpression 
or knockdown of chemokine receptor CXCR7 in Sca1+ cells resulted in alterations in cell 
migration. Co-Immunoprecipitation experiments using Sca1+ cells extracts treated with Dkk3 
showed the physical interaction between DKK3 and CXCR7, and specific saturation binding 
assays identified a high affinity Dkk3-CXCR7 binding with a dissociation constant (Kd) of 
14.14 nM. Binding of CXCR7 by Dkk3 triggered the subsequent activation of ERK1/2, 
PI3K/AKT, Rac1 and RhoA signalling pathways involved in Sca1+ cell migration. TEVGs 
were fabricated with or without Dkk3 and implanted to replace the rat abdominal aorta. Dkk3-
loaded TEVGs showed efficient endothelization and recruitment of VPCs, which had 
acquired characteristics of mature smooth muscle cells. CXCR7 blocking using specific 
antibodies in this vessel graft model hampered stem/progenitor cell recruitment into the 
vessel wall, thus compromising vascular remodelling.  
Conclusions: We provide a novel and solid evidence that CXCR7 serves as Dkk3 receptor, 
which mediates Dkk3-induced vascular progenitor migration in vitro and in tissue-engineered 
vessels, hence harnessing patent grafts resembling native blood vessels.   
 
Key words: Dkk3, stem/progenitor cells, migration, tissue-engineered vessel grafts, vessel 
remodelling. 
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NON-STANDARD ABBREVIATIONS AND ACRONYMS 
 
AKT or PKB: Protein Kinase B 
AP: Alkaline Phosphatase 
ApoE: Apolipoprotein E 
BrdU: Bromodeoxyuridine 
Dkk3: Dickkopf-3 
EC: Endothelial cell 
ERK1/2: Extracellular signal–regulated kinases 1/2 
GFP: Green fluorescent protein 
Kd: Dissociation constant 
LRP5/6: Low-density lipoprotein receptor-related protein 5 or 6 
MLC: Myosin light chain 
PCL: Polycacoprolactone 
PI3K: Phosphatidylinositol 3-kinase 
Rac1: Ras-related C3 botulinum toxin substrate 1 
RhoA: Ras homolog gene family, member A 
ROCK: Rho-associated protein kinase 
Sca-1: Stem cell antigen-1 
Sdf-1α: Stromal cell-derived factor 1 alpha 
SEM: Scanning Electron Microscope 
SMC: Smooth muscle cell 
SMPC: Smooth muscle progenitor cells 
SM-MHC: Smooth muscle myosin heavy chain 
TEVGs: Tissue engineered vessel grafts 
VPCs – Vascular progenitor cells 
vWF: Von Willebrand factor 
α-SMA: alpha smooth muscle actin 
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INTRODUCTION 
Coronary and peripheral vascular bypass surgeries are one of the most effective treatments 
for cardiovascular diseases, in which autografts constitute the standard clinical approach for 
blood vessel replacement1. However, due to disease or previous harvesting, autologous 
vessels have limited availability. As an alternative, tissue-engineered vessel grafts (TEVGs) 
composed of synthetic or biodegradable polymers have been developed2, 3. Although with 
apparent potential, their clinical application has been challenged by unsuccessful long-term 
patency due to intimal hyperplasia and thrombosis. The design of patent vascular grafts, 
capable of inducing vascular remodelling, adequately integrating into the native blood 
vessel, and displaying the required mechanical strength to withstand the blood pressure, 
greatly relies on host cell recruitment, particularly of vascular progenitor cells (VPCs)4, 5.  
Accumulating evidence has shown that stem/progenitor cells play an active role in vascular 
remodelling6-9. Amongst these cells, it has been demonstrated that vessel wall resident 
VPCs are able to migrate, proliferate and differentiate into different cell lineages, including 
endothelial and smooth muscle cells10-12. Our group has identified a population of multipotent 
and lineage committed progenitor cells, e.g. Sca-1+, c-kit+, CD34+ and Flk1+ cells, resident 
in the aortic adventitia of ApoE-deficient mice13. In experimental vein graft and wire-induced 
arterial injury mouse models, the adventitia-derived Sca-1+ progenitor cells transferred to 
the perivascular side of the vessel were able to migrate to the neointima and to differentiate 
into smooth muscle cells (SMCs), with contribution to vascular remodelling and 
atherosclerotic lesion enhancement13, 14. More recently, a study demonstrated that a 
subpopulation of Sca-1+ cells originates from differentiated medial SMCs and that these 
cells not only exhibit a multipotent phenotype but can also expand and contribute to 
adventitial remodelling following vascular injury15. However, little is known about the 
molecular mechanisms of vascular progenitor cell recruitment in vivo. 
Dickkopf-3 (Dkk3) is a secreted glycoprotein, highly expressed in endothelial cells (ECs), 
SMCs and platelets16-19. Functionally, Dkk3 was found to play important roles in 
cardiovascular biology. Previous reports had already demonstrated that Dkk3 can protect 
against cardiac hypertrophy20, 21 and our group recently showed that Dkk3 is an 
atheroprotective cytokine. Indeed, in a human population-based prospective study, Dkk3 
serum level was inversely correlated with carotid artery intimal thickening19. These findings, 
together with the potential of Dkk3 to induce SMC differentiation of stem cells16, 17 led us to 
investigate its effect on VPCs and vascular regeneration, which remains unknown. 
Mechanistically, a great controversy surrounds the identification of Dkk3 receptor. Some 
studies have shown that, contrary to Dkk1, Dkk2 and Dkk4, Dkk3 is not able to bind to Wnt 
pathway components Kremen1, Kremen2, LRP5 and LRP622-26. On the other hand, 
contradictory reports have indicated that Dkk3 could interact with these receptors16, 25, 27. We 
hypothesized that Dkk3 could act as a chemokine for VPCs possibly via binding to a 
chemokine receptor. In this work, we identify CXCR7 as the functional chemokine receptor 
for Dkk3 and elucidate the downstream migration-related pathways ERK1/2, PI3K/AKT and 
Rho GTPases. We also designed Dkk3-loaded TEVGs and showed that they exhibit long-
term patency with controlled recruitment and differentiation of VPCs, thus harnessing 
neoarteries resembling native blood vessels. CXCR7 blocking in this model inhibits VPCs 
recruitment and compromises graft remodelling.  
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Methods 
The data that support the findings of this study are available from the corresponding author 
on reasonable request. 
Details of materials and experimental procedures are available in the Online Data 
Supplement. 
Sca-1+ Adventitial Progenitor Cell Isolation and Dkk3 Binding 
Mouse vascular progenitor cells were isolated from the outgrowth of aortic adventitial tissues 
as previously described13. Sca-1+ VPCs were treated with 25 ng/mL of Dkk3 for 3 hours. 
The lysate was pre-cleared by using the Control Agarose Resin column. The eluted immune 
complexes and input samples were separated on a 4-12% Bis-Tris gel and the immunoblot 
was probed with Dkk3 antibody. His-tag pull-down assay was performed according to the 
instructions provided in MagneHis Protein Purification System (Promega). Receptor affinity 
binding assay was done as described previously22.  
 
Results 
Dkk3 Induces Migration of Resident Sca-1+ Vpcs In Vitro And Ex Vivo 
To investigate the chemotactic potential of Dkk3 in Sca-1+ cells, we first performed in vitro 
migration assays. Sdf-1α chemokine was used as a positive control for cell migration in the 
experiments28, 29. Transwell and wound healing assays revealed that Dkk3 markedly induced 
the migration of Sca-1+ cells over a range of concentrations of 0-100 ng/mL (Figure 1a, b, d 
and e), indicating that Dkk3 possesses chemokine-like properties comparable to Sdf-1α 
(Figure 1a, c, d and f). To rule out a potential contribution of Dkk3-induced Sca-1+ cell 
proliferation in our observations, we performed BrdU incorporation cell proliferation assay at 
16, 24 and 48 hours of treatment. No significant differences were observed in the cell 
proliferation rate of the cells between control and treatment groups, when the dose of 25 
ng/mL of Dkk3 was used (Online Figure Ia). Dkk3 treatment at higher concentration (50 
ng/mL) promoted cell proliferation only after 48 hours of treatment. The effect of Dkk3 on cell 
death by apoptosis and necrosis was also determined. During the 24 hours of treatment (25 
ng/mL), no significant difference in cell death rate was found between control and Dkk3 
groups (Online Figure Ib). We thus concluded that Dkk3 induces the chemotaxis of Sca-1+ 
cells in vitro. To further assess the chemotactic effect of Dkk3 in a setting that better mimics 
the in vivo 3-dimensional conditions and to study the effect of Dkk3 on endogenous resident 
VPCs of the vessel wall, the aortic ring assay was performed with aortas of wild type and 
ApoE-/- mice. In wild type explants, although Dkk3 induced cell outgrowth, no difference with 
statistical significance was observed between control and Dkk3 treated group (Figure1 g-h). 
However, in ApoE-/- explants, Dkk3 remarkably promoted cell outgrowth from the aortic rings, 
analogously to Sdf-1α (Figure 1g and i). The explanation could be that vascular cells derived 
from the native atherosclerosis model ApoE-/- mice are potentially more responsive or 
sensitive to stimuli than the cells derived from wild type mice. We have shown in a previous 
study that, compared to wild type cells, ApoE-/- Sca1+ cells exhibit an altered expression of 
genes implicated in cell migration, including matrix metallopeptidases and integrins, and 
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possess an intrinsically enhanced migratory potential30. As cell outgrowth from the aortic 
rings comprises different cell types, we next sought to examine the contribution of Sca-1+ 
progenitor cells in Dkk3-induced outgrowth. Aortic rings from transgenic Sca-1-GFP ApoE-/- 
mice were isolated and cultured, as this mouse model allows rapid detection of Sca-1+ cells, 
through green fluorescence protein (GFP) expression. Dkk3 treatment triggered an increase 
in Sca-1+-GFP+ cell outgrowth compared to control (Figure 1j-k). Moreover, the percentage 
of Sca-1+-GFP+ cells in the total number of outgrown cells was also higher in Dkk3 
treatment group than in control group (Figure1j and l). These results further confirmed the 
chemotactic role of Dkk3 in resident Sca-1+ VPCs with an efficiency comparable to Sdf-1α. 
CXCR7 Is Involved In Dkk3-Driven Migration Of Sca-1+ Cells 
The similarity of action between Dkk3 and Sdf-1α prompted us to investigate if the receptors 
of Sdf-1α, CXCR4 and CXCR7, could participate in Dkk3-mediated migration of Sca-1+ 
cells. Flow cytometry analysis revealed that most of Sca-1+ cells expressed CXCR7 
(77.9%±6.2%), whereas few Sca-1+ cells displayed CXCR4 on their surface (0.9%±0.2%) 
(Figure 2a and b). Few cells were positive for both receptors (1.1%±0.2%) and all the cells 
expressing CXCR4 also expressed CXCR7. Western blot analysis further confirmed the high 
expression of CXCR7 in Sca-1+ cells (Figure 2c). Noticeably, contrary to Sca-1+ cells, 
SMCs and ECs significantly expressed both CXCR4 and CXCR7. We speculate that CXCR7 
may potentially be a vascular stem cell receptor, which is supported by previous studies that 
report a high expression of CXCR7 in progenitor cells31-33. To assess the potential 
involvement of CXCR7 in Dkk3- and Sdf-1α-driven Sca-1+ cell migration, we performed 
transwell migration assays on progenitors following efficient knockdown of CXCR7 by siRNA 
targeting. Downregulation of CXCR7 was confirmed by real time qPCR (Figure 2d) and 
western blot (Figure 2e) analysis. CXCR7 downregulation induced strong decrease in Dkk3-
driven Sca-1+ cell migration (Figure 2f and g), comparable to the decrease observed in Sdf-
1α-driven cell migration (Figure 2h and i). Our findings proved that CXCR7 was involved in 
Sca-1+ cell migration induced by Dkk3. Due to the low expression of CXCR4, a different 
strategy was employed to inhibit its functional activity. Migration assays were performed 
using CXCR4 inhibitor AMD3100, at three different concentrations: 10, 25 and 50 µM 
(Online Figure IIa-b). Inhibition of CXCR4 had no effect on the migration rate of Sca-1+ cells 
in the presence of either Dkk3 or Sdf-1α. This suggested that CXCR4 receptor was not 
implicated in either Dkk3- or Sdf-1α-mediated migration of Sca-1+ cells. 
CXCR7 Is A High-Affinity Binding Receptor Of Dkk3 
To verify the physical interaction between Dkk3 and CXCR7 we performed a co-
immunoprecipitation assay. CXCR7 from lysates of Sca-1+ cells treated with Dkk3 was 
pulled down using anti-CXCR7 antibody and co-precipitated with Dkk3, as revealed by 
Western blot, with a corresponding band displayed in the input sample and not when an IgG 
control antibody was used (Figure 3a). We also conducted a reverse pull-down assay, in 
which Dkk3-His tagged was pulled-down from Sca-1+ cell lysate and eluted with any bound 
CXCR7 (Figure 3b). Noticeably, contrarily to CXCR7, CXCR4 was not pulled-down with 
Dkk3. To measure the affinity of the interaction between Dkk3 and CXCR7, saturation 
binding experiments were performed as previously described22, 23. The measurement of Sdf-
1α binding affinity to CXCR4 and CXCR7 was used to validate the design of the experiment. 
Dkk3 and Sdf-1α were conjugated with alkaline phosphatase (AP) and the efficiency of AP 
conjugation was confirmed by determining the AP activity following serial dilutions (Online 
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Figure IIIa-b). Next, CXCR7 and CXCR4 receptors (HA-tagged) were overexpressed in HEK 
293T cells (Figure 3c-d and Online Figure IIc-d) and the corresponding cell lysates were 
loaded onto the wells of high-affinity binding ELISA plates previously coated with anti-HA 
antibody. Sdf-1α-AP bound with high affinity to CXCR4 and CXCR7, as characteristic 
hyperbolic curves were obtained for each receptor (Figure 3e). The dissociation constant 
(Kd) for CXCR4 (10.05 nM) was comparable to that calculated for CXCR7 (4.93 nM), 
indicating comparable strength of affinity for Sdf-1α. Dkk3-AP also bound with high affinity to 
CXCR7, which was represented by the typical hyperbolic binding curve and a Kd of 14.14 
nM (Figure 3f). The binding curve observed for CXCR4 was also indicative of absence of 
Dkk3 binding. To rule out the possibility that AP itself could bind to CXCR7, a serial dilution 
of AP alone was performed. The results showed only a residual binding (Figure 3e-f).As 
Kremen1 and Kremen2 were identified as functional receptors for members of the Dkk 
family22, we also assessed their binding affinity to Dkk3. Sca-1+ VPCs express Kremen1, but 
display a low expression of Kremen2 (Online Figure IVa-b). In addition, Kremen1 was 
neither pulled-down with Dkk3-His-tagged (Online Figure IVc), nor it co-immunoprecipitated 
with CXCR7 (Online Figure IVd), in Sca-1+ VPCs.  In the saturation binding assay, 
ambiguous binding curves were obtained for Kremen1 and Kremen2, suggesting that Dkk3 
could not bind to these receptors (Figure 3e). . Kremen1 downregulation by SiRNA 
transfection also did not affect significantly Dkk3-induced migration of Sca-1+ cells (Online 
Figure IVe-g). Finally, Dkk3 also increased the migration rate of CXCR7-overexpressing 
HEK cells in comparison with the non-treated control group (Figure 3g-h), whereas 
overexpression of Kremen1 and Kremen2 did not modify Dkk3-mediated HEK cell migration 
(Online Figure IVh-m). Treatment with Sdf-1α also resulted in an increase of the migration 
rate of CXCR7 overexpressing cells (Figure 3i-j). Not surprisingly, Sdf-1α induced the 
migration of cells overexpressing CXCR4, when compared to non-treated control group 
(Online Figure IIg-h). However, Dkk3 treatment had no effect on the migration rate of 
CXCR4 overexpressing cells (Online Figure IIe-f). We thus concluded that Dkk3 not only 
binds with high affinity to CXCR7, but also that CXCR7 is a functional receptor for Dkk3.  
ERK1/2 and PI3K/AKT Signalling Pathways Act Downstream Of Sca-1+ Cell Migration  
MAPK kinases (such as ERK1/2) and PI3K/AKT pathways are classical signalling cascades 
involved in cell migration triggered by the activation of chemokine receptors34, 35. Having 
established the chemotactic role of Dkk3 and its effective binding to chemokine receptor 
CXCR7, we next sought to investigate whether these pathways were involved in Sca-1+ cell 
migration induced by Dkk3 binding to CXCR7. Changes in the phosphorylation level of 
ERK1/2 and AKT were examined by Western blot after 0 to 15 minutes of Dkk3 stimulation. 
Dkk3 treatment induced ERK1/2 and AKT phosphorylation (Figure 4a and b). Stimulation 
with Sdf-1α also increased ERK1/2 and AKT phosphorylation (Online Figure Va and c). Sdf-
1α-mediated ERK1/2 and AKT phosphorylation and consequent induction of cell migration 
have been shown before in previous studies36-38. We provide solid evidence of the 
implication of ERK1/2 and PI3K/AKT pathways in the mechanisms of cell migration 
promoted by Dkk3. Treatment with PD98059 and LY294002 inhibited, respectively, ERK1/2 
and AKT phosphorylation induced by Dkk3 (Figure 4e and f) and Dkk3-induced cell 
migration (Figure 4g and h). Specific AKT inhibitor (AKT inhibitor X) also decreased Dkk3-
driven migration of Sca-1+ cells (Figure 4i). Furthermore, knockdown of Akt and Erk 
pathways by SiRNA transfection (Online Figure6).  Altogether, our data showed that ERK1/2 
and PI3K/AKT signalling pathways were required for Sca-1+ cell migration induced by Dkk3. 
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Interestingly, Sdf-1α-mediated migration of Sca-1+ cells shared the same signalling 
mechanisms (Online Figure Va-e). Furthermore, CXCR7 siRNA mediated downregulation in 
Sca-1+ cells led to a decrease in Dkk3-driven ERK1/2 and AKT phosphorylation (Figure 4c 
and d), which showed that CXCR7 activation by Dkk3 acts upstream these signalling 
pathways. 
Rac1 and Rhoa GTPases Activation is Required  
Rho GTPases are well known for their role in cytoskeleton rearrangement and cell migration. 
Quantification of the active GTP-bound Rac1 and RhoA forms in Sca-1+ cells was assessed 
by performing G-LISA activation assay at early time points of Dkk3 stimulation (0-30 
minutes) and showed that Dkk3 triggered the activation of Rac1 and RhoA (Figure 5a and 
e). Transwell migration assays were performed in the presence of Rac1 activation inhibitor 
NSC23766. NSC23766 efficiently inhibited Rac1 activation (Figure 5c) and resulted in a 
decrease in the migration rate of Sca-1+ cells induced by Dkk3 (Figure 5d). Treatment of 
Sca-1+ cells with RhoA inhibitor Rhosin blocked Dkk3-induced RhoA activation (Figure 5g) 
and abolished Dkk3-mediated Sca-1+ cell migration (Figure 5h). SiRNA mediated 
knockdown of CXCR7 in the cells abolished the Dkk3-triggered activation of Rac1 and RhoA 
(Figure 5b and f), which reveals that Rho GTPases activation induced by Dkk3 requires 
Dkk3 binding to CXCR7. The phosphorylation level of myosin light chain (MLC), a 
downstream effector of RhoA, in response to Dkk3 stimulation was also assessed. In the 
presence of Dkk3, MLC phosphorylation at early time points was increased (Figure 5i). Rho 
associated kinases (ROCK) are activated by RhoA and can induce phosphorylation of MLC. 
Therefore, we investigated whether ROCK inhibitor Y27632 could repress MLC 
phosphorylation. Y27632, not only reduced Dkk3-triggered phosphorylation of MLC (Figure 
5j), but also decreased the migratory ability of Sca-1+ cells stimulated by Dkk3 (Figure 5k). 
Finally, as RhoA can also directly phosphorylate MLC, we examined if Rhosin could affect 
MLC activation. Inhibition of RhoA with Rhosin reduced the Dkk3-triggered phosphorylation 
of MLC (Figure 5j). Collectively, these results showed that Rac1 and RhoA GTPases are 
involved in Sca-1+ cell migration mediated by CXCR7 activation induced by Dkk3 binding. 
Finally, to investigate whether Rac1 and ERK1/2 signalling pathways were interacting with 
each other, we measured the Dkk3-driven phosphorylation level of ERK1/2 in the presence 
of Rac1 inhibitor, and the Dkk3-triggered activation of Rac1 upon treatment with ERK 
inhibitor. Dkk3-induced phosphorylation of ERK1/2 was supressed in response to NSC23766 
treatment (Online Figure VIIa). Surprisingly, Rac1 activation triggered by Dkk3 was also 
repressed upon treatment with PD98059 (Online Figure VIIb). These results indicated a 
possible feedback mechanism between ERK1/2 and Rac1. In contrast, Rac1 and RhoA 
activation stimulated by Dkk3 was not affected upon treatment with PI3K/AKT inhibitor 
LY294002 (Online Figure VIIc-d). Interestingly, treatment with Sdf-1α also promoted the 
activation of Rac1 and RhoA and phosphorylation of MLC (Online Figure Vf-h). 
As Dkk proteins have been associated with the Wnt signalling pathway39, 40, we assessed 
whether this pathway was implicated in Dkk3-driven cell migration. Dkk3 stimulation had no 
effect in the expression of β-catenin, Axin-2 and Tcf1 (Online Figure VIIIa-d). Furthermore, 
24 hours of Dkk3 stimulation did not activate the transcription of Wnt target genes, given that 
the luciferase activity did not modify in the presence of Dkk3 (Online Figure VIIIe). Treatment 
of Sca-1+ cells with FH535, a specific inhibitor of the canonical Wnt/β-Catenin signalling 
transduction pathway, resulted in an increase of cell migration, comparable to the increase 
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obtained when the cells were treated with Dkk3 (Online Figure VIIIf). However, when cells 
were treated with Dkk3 combined with FH535, no cumulative effect and difference were 
found in the cell migration rate between this group and the group treated only with Dkk3. 
Inhibition of Dishevelled protein, a critical component of both canonical and non-canonical 
Wnt pathways, with Peptide Pen-N3 (Dvl-PDZ), also did not affect Dkk3-triggered migration 
of Sca-1+ cells (Online Figure VIIIg), as no difference was found between Dkk3-treated 
group and the group treated with Dkk3 combined with the Peptide Pen-N3. Therefore, we 
concluded that the Wnt signalling pathway is not involved in Sca-1+ cell migration induced 
by Dkk3. 
Characterisation and Patency of Dkk3-Loaded Tissue Engineered Vessel Grafts 
(TEVG) In Rat Model 
To evaluate the role of Dkk3 in cell migration in vivo, TEVGs were evaluated by rat 
abdominal aorta replacement model (Online Figure IXa left top). Dkk3-loaded TEVGs (2.0 
mm in diameter and 500 µm in wall thickness) were fabricated by co-electrospinning 
technique, then implanted into the abdominal artery of rats and examined at different time 
points. Scanning electronic microscopy showed homogeneous fibrous structure of the grafts 
(Online Figure X), consisting of PCL microfibers (~6 µm) and collagen nanofibers (~600 nm). 
PCL microfibers provided good mechanical support and macroporous structure, while 
collagen nanofibers introduced a biocompatibility and acted as carriers for Dkk3. With the 
degradation of the collagen fibers, Dkk3 was released from the grafts in a sustained manner 
and no burst release was observed during the detection period (Online Figure XI). Unloaded 
grafts were used as controls for comparison to determine the effect of loaded Dkk3. 
Ultrasound analysis at 2 weeks, 1 and 3 months (Online Figure IXa right) indicated that most 
of the implanted grafts were patent and presented sustained blood flow, without aneurysm, 
bleeding, or occlusion (Online Figure IXc). Some capillaries could be observed from the 
adventitia of the implanted grafts, which reflects their integration with the surrounding tissues 
(Online Figure IXa left bottom). Micro-CT revealed that no detectable calcification occurred 
in both groups at 3 months post-implantation (Online Figure IXb). 
Delivery of Dkk3 in Tissue TEGVs Enhances Vascular Regeneration 
We then investigated whether Dkk3 could promote vascular cellularisation and regeneration 
of the vascular grafts. Haematoxylin & Eosin staining showed that the luminal diameter was 
markedly preserved in patent grafts without narrowing caused by intimal hyperplasia 3 
months post-implantation (Figure 6a and Online Figure XII). Moreover, no significant 
difference in the inner diameter could be seen between Dkk3 and control groups at each 
time point (Figure 6b). DAPI staining revealed sufficient cell infiltration into the graft wall after 
2 weeks, which is crucial for the following vascular regeneration (Online Figure XIII)3. After 3 
months implantation, electron microscopy images throughout the vessel graft revealed that 
grafts loaded with Dkk3 were covered by a nearly confluent layer of neo-tissue, uniformly 
aligned along the blood flow, with a more homogeneous organization, when compared to 
control group (Figure 6c).   
The effect of Dkk3 on vascular smooth muscle regeneration was evaluated by 
immunofluorescence staining using α-SMA and SM-MHC antibodies, and subsequent 
measurement of the total area of α-SMA+ and SM-MHC+ cells in the luminal region in 
control and treated grafts. 2 weeks post-implantation, Dkk3 treated grafts showed a 
significantly greater SMA+ area within the lumen region compared to the untreated grafts, 
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but no difference could be measured anymore between the two groups one-month post-
implantation, indicating that Dkk3 promoted the recruitment of α-SMA+ cells in the graft at an 
early stage (Figure 6d-e). Interestingly, at later stages, i.e. 1 (p<0.01) and 3 (p<0.005) 
months post-implantation, the SM-MHC+ area within the lumen region was significantly 
higher in the Dkk3 group in comparison with the control group (Figure 6d and f). These 
results demonstrated that Dkk3 promoted vascular regeneration by increasing the proportion 
of mature and functional SMCs, while reducing the over-proliferation of SMCs that may lead 
to adverse intimal hyperplasia. Dkk3-TEVGs exhibited increased expression of SM-MHC 
and Calponin and a reduced expression of α-SMA, in comparison to control-TEVGs (Online 
Figure XIVa). Double immunofluorescence staining of α-SMA and SM-MHC further 
demonstrated that Dkk3 induced the transition of SMCs toward a contractile phenotype, 
exhibiting the typical spindle-shaped morphology (Online Figure XIVb). 
Graft endothelization was analysed by immunofluorescence staining with vWF antibody. 
Endothelial cells were first observed at 2 weeks post-implantation in both groups. After 3 
months of implantation, the vWF+ cell layer in the Dkk3 group appeared more uniform and 
continuous, characteristics of a more mature endothelium composed of a thin single sheet of 
ECs (Online Figure XV). These results are consistent with a recent study published by our 
group, which shows that Dkk3 accelerated re-endothelization in a femoral artery wire injury 
mouse model, confirming the role of Dkk3 on vascular endothelium integrity and function19. 
Furthermore, double immunofluorescence staining of vWF and α-SMA also revealed a better 
tissue organisation in Dkk3 group compared to the control group, as shown by the several 
layers of SMCs strategically aligned beneath a uniform layer of neo-endothelium (Online 
Figure XVI). Concomitantly, the detection of extracellular matrix proteins, including elastin 
and collagen by Masson and Verhoeff-Van Gieson staining, showed a significant increase in 
the deposition of extracellular matrix content in the Dkk3 group at 1 and 3 months post-
implantation (Online Figure XVII). Taken together, these results show that Dkk3 enhances 
TEVG cellularisation and remodelling, important processes involved in blood vessel 
maturation. 
Dkk3 Increases Sca-1+ Progenitor Cell Migration Through CXCR7 Activation And 
Contributes To Vascular Smooth Muscle Regeneration 
Next, the specific effect of Dkk3 on Sca-1+ progenitor cells was further evaluated in our graft 
model, and the result indicated that incorporation of Dkk3 in the TEVGs remarkably 
enhanced the infiltration and maintenance of Sca-1+ stem/progenitor cells within the graft 
wall (Figure 7b-c). Furthermore, double immunofluorescence staining of α-SMA and Sca-1 
(Figure 7d) showed a greater number of double positive cells in Dkk3-loaded TEVGs 
compared with control group, indicating that some mobilized Sca-1+ cells could directly 
differentiate into SMCs and participate in the regeneration of vascular smooth muscle. To 
confirm the role of CXCR7 receptor in the Dkk3-driven migration of Sca-1+ progenitor cells, 
double-layered vascular grafts were designed and evaluated in in vivo models. In detail, in 
addition to the Dkk3-loaded inner layer, a CXCR7 antibody-loaded layer was introduced at 
the outside of the graft (Figure 7a). Due to the antagonistic effect provided by the CXCR7 
antibody, the number of infiltrated Sca-1+ cells was dramatically reduced (Figure 7b-c), 
confirming that the chemotactic role of Dkk3 is dependent on CXCR7 activation. 
Furthermore, blocking of CXCR7 decreased the Dkk3-induced number of cells double 
positive for Sca-1+ and α-SMA cells infiltrated into the grafts at 2-weeks and 1-month post-
11 
 
implantation (Figure 7d). The effect of CXCR7 blocking in the grafts was also assessed for 
ECs, SMCs and macrophages. The increased α-SMA+ area in Dkk3-TEVGs was reduced 
upon CXCR7 blocking at 2-weeks and 1-month post-implantation (Online Figure XVIIIa-b). 
Likewise, SM-MHC+ area was also decreased in Dkk3-TEVGs when CXCR7 was blocked 
(Online Figure XVIIIa and c). Regarding the ECs, at 1-month post-implantation, although no 
difference was observed between control and Dkk3 groups in the endothelial coverage of the 
grafts, CXCR7 blocking decreased the graft endothelial coverage in the Dkk3-TEVGs 
(Online Figure XIX). Finally, no difference was detected in the recruitment of macrophages 
between control and Dkk3 groups or when CXCR7 blocked, at 1-month post-implantation 
(Online Fig XX). Interestingly, at 1-month post-implantation, Dkk3 does not change in vivo 
the proliferation rate of ECs, SMCs and macrophages (Online Figure XXI). Sdf-1α-TEVGs 
were also fabricated to further assess if CXCR7 acts as a regulator of regeneration. At 2-
weeks post-implantation, similarly to Dkk3, Sdf-1α also induced the recruitment of Sca-1+ 
VPCs into the grafts, which was reduced upon CXCR7 blocking (Online Figure XXII). 
Interestingly, macrophage recruitment was higher in Sdf-1α-TEVGs than in control-TEVGs, 
and CXCR7 blocking decreased the Sdf-1α-induced migration of macrophages. On the other 
hand, no differences were observed between control and Sdf-1α groups in the recruitment of 
SMCs and in the endothelial coverage of the grafts. These results confirm that Dkk3-CXCR7 
axis is crucial in mediating Sca-1+ cell migration and graft cellularisation and regeneration in 
vivo. 
 
Discussion 
Previous studies have reported that Sca-1+ progenitor cells are able to migrate and 
differentiate into a variety of cells and participate in vascular repairing and remodelling13, 28, 
29, 41. In this study, we demonstrated that Dkk3 induces chemotaxis for Sca-1+ 
stem/progenitor cells via binding specifically to CXCR7 resulting in better regeneration of 
tissue engineered vessel grafts. These conclusions are based on the following observations. 
Firstly, Dkk3 can induce vascular progenitor migration in vitro in both transwell and wound 
healing assays and ex vivo in organ 3D culture assays using Sca-1-GFP aortic rings. 
Secondly, Dkk3 physically interacts with CXCR7 as indicated by co-immunoprecipitation and 
His-tag pull-down analysis, ligand-receptor affinity binding assays, artificial CXCR7-
expressing system chemotaxis assay and receptor blocking assays. Thirdly, downstream 
signalling pathways mediated by Dkk3-CXCR7 binding were identified and confirmed using 
chemical inhibition and functional migration assays. Finally, Dkk3-loaded engineered vessel 
grafts displayed enhanced cellularization in vivo that could be blocked by application of anti-
CXCR7 antibodies. Thus, the discovery of a new functional role for Dkk3 and the 
identification of its functional receptor could provide the basic information for the 
development of new drugs for vascular disease. 
Chemokines are a class of cytokines that direct cell migration by binding to their 
corresponding chemokine receptor present on target cell types. The most important question 
is whether the chemotaxis of stem/progenitor cells is activated via binding of Dkk3 to a 
chemokine receptor. The chemokine receptors profile on Sca-1+ cells has been previously 
investigated through a systematic PCR array analysis, and the result showed that CXCR7 
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expression was remarkably higher than the expression of all the other receptors14. Because 
CXCR7 is a receptor of Sdf-1α (a well-known chemokine with an established role in inducing 
chemotaxis of various cell types, including SMCs, ECs and Sca-1+ VPCs28, 29, 42, 43), we 
investigated whether CXCR7 could be the receptor of Dkk3 considering the similarity in the 
chemotactic ability between Dkk3 and Sdf-1α. In line with published data, our results 
confirmed that most Sca-1+ cells considerably expressed CXCR7, while the expression of 
the other receptors of Sdf-1α, such as CXCR4, was significantly low. Interestingly, as 
reported for Dkk3, CXCR7 expression is also upregulated in several cancers and tumour 
associated vasculature, which confers a pro-angiogenic role to CXCR744, 45. Originally, 
CXCR7 was recognized as a mere scavenger receptor with the function to generate 
gradients of Sdf-1α46, 47. More recently, it is accepted as a functional receptor directly 
involved in cellular responses, including cell migration33, 36, 48-50. In this study, knockdown of 
CXCR7 abrogated Dkk3-driven migration of progenitors, whereas CXCR7 overexpression 
increased Dkk3-mediated cell migration. Our data revealed that CXCR4 inhibition had no 
effect in Dkk3- or Sdf-1α-mediated migration of Sca-1+ cells, which indicated that CXCR4 
was not implicated in this process. These results were consistent with previous studies 
which showed that CXCR4 antagonism with AMD3100 did not always inhibit Sdf-1α-induced 
migration, as the chemokine acted via CXCR750, 51. Collectively, our results demonstrate that 
CXCR7 is involved in Dkk3-driven migration of Sca-1+ cells. 
Our data demonstrated that Dkk3 binds to CXCR7 with high affinity and in a specific, dose 
dependent and saturable manner. The strength of their binding affinity was comparable to 
the interactions between Sdf-1α and CXCR7 or CXCR4, which were consistent with the 
reported data49, 52. Remarkably, our results are also in accordance with the findings 
described by Mao et al, that, contrarily to Dkk1 and Dkk2, Dkk3 does not bind to Kremen1 
and Kremen222, 24. Our findings provide the direct evidence of physical binding of Dkk3 to 
CXCR7, which may serve as a Dkk3 receptor.   
Among the multiple molecular mechanisms that regulate cell migration, we found that 
ERK1/2, PI3K/AKT, Rac1 and RhoA signalling cascades were involved in Sca-1+ VPCs 
migration induced by Dkk3. Dkk proteins are classically associated with the Wnt signalling 
pathway, which comprises the canonical (β-catenin dependent) and the non-canonical (β-
Catenin independent) pathways39, 40. Unlike the other members of the Dickkopf family which 
are Wnt/β-Catenin pathway antagonists39, 40, Dkk3, according to specific cell context, can act 
either as an agonist or inhibitor of the canonical Wnt signalling25, 53, or even exerts its effect 
independently of the Wnt pathway19, 24. Our findings show that none of the Wnt signalling 
pathways is implicated in the migration mechanism of Sca-1+ cells stimulated by Dkk3. 
Noticeably, Sdf-1α induced the same migration molecular mechanisms. This result, allied 
with the fact that Dkk3 is the most divergent member of the Dicckopf family by several 
criteria40, 54, further supported our hypothesis of the chemotactic role of Dkk3 in 
stem/progenitor cells through CXCR7 activation. Finally, the molecular mechanisms involved 
in Dkk3-driven Sca-1+ cell migration are summarized in Figure 8. 
Encouraged by the chemotactic properties of Dkk3 demonstrated from in vitro and ex vivo 
assays, we further assessed the role of Dkk3 in the migration of Sca-1+ progenitor cells in 
vivo and evaluated its potential to harness endogenous vascular regeneration by using a 
tissue engineered vessel graft model. Dkk3-loaded tissue engineered grafts effectively 
promoted the infiltration of Sca-1+ progenitor cells into the grafts, which was abrogated after 
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the incorporation of CXCR7 antibody. Consistent with our results, studies have reported that 
Sdf-1α-loaded vascular grafts  display an increased recruitment of endogenous progenitor 
cells and accelerate vascular regeneration. Additionally, these cells expressed CXCR7 and 
appeared to be progenitors of endothelial and smooth muscle cells2. Our results also confirm 
the similarity between Dkk3 and Sdf-1α in terms of chemotactic function, and establish the 
Dkk3-CXCR7 axis as regulator of regeneration. 
An intact endothelial cell monolayer and the presence of mature SMCs in the media is vital 
in preventing thrombogenesis and maintaining long-term patency of vessel grafts55. The 
ability of Dkk3 to promote re-endothelialisation has been demonstrated in different models19, 
56, 57. Our study revealed that DKK3 promoted endothelialisation in TEVGs, which exhibited a 
more uniform and organized alignment of endothelial cells along the blood flow. Vascular 
cellularisation and remodelling, which relies on the generation of a functional tunica media, is 
a critical aspect in TEVGs. Previous studies have demonstrated that Sca-1+ stem/progenitor 
cells can differentiate into SMCs under the stimuli of various cytokines13, 28, 29, 41, 58, including 
Dkk316, 17, 59. In this study, Dkk3-loaded TEVGs exhibited a greater number of Sca-1+ cells, 
which co-expressed α-SMA. In vivo blocking of CXCR7 lead to a decreased number of 
SMCs present in the TEVGs, which may be due to the preceding reduction in the recruitment 
of VPCs into the TEVGs, that have the ability to migrate and differentiate into SMCs 
promoted by Dkk3 stimulation. More importantly, the SMC phenotype in Dkk3-TEVGs 
switched to a more mature and contractile phenotype in comparison to control TEVGs. 
Recently, we published a study proving the ability of Dkk3 to induce the differentiation of 
Sca-1+ VPCs into SMCs59.The neo-vessel of Dkk3-loaded TEVGs exhibited a better tissue 
organization in structure with several SMC layers aligned beneath the endothelium, thus 
resembling that of native arteries. Therefore, our data show that Dkk3, through CXCR7, 
promotes better restructuration of the TEVGs and communication between the endothelial 
and SMC layers, which potentially contributes to a better endothelization of the vessel. 
Additionally, Dkk3 release over time increased the production of extracellular matrix, which is 
essential to provide the required mechanical strength to withstand the arterial pressure. The 
deposition of elastin and collagen was associated with the maturation of the smooth muscle 
layer, which supported the role of Dkk3 in promoting vascular graft arterialisation. These 
findings are consistent with a recent study which reports that Dkk3, not only induces the 
differentiation of Sca-1+ VPCs into SMCs, but also increases the content in SMCs and 
extracellular matrix deposition in atherosclerotic plaques, thus having a plaque stabilizing 
effect59. The functionality of the TEVGs has been assessed previously60. After 12 months 
implantation, our TEVGs grafts contracted and relaxed appropriately in response to the 
respective stimulants, thus proving that regenerated contractile SMCs were present in the 
grafts, which displayed a good vasoactivity, although still not at the level of the native vessel 
because of the slow degradation of the graft material. Furthermore, at 12-months 
implantation, all the grafts were patent, with absence of calcification, aneurism, stenosis, or 
harmful remodeling, and exhibited rapid endothelization. Considering the ability of Dkk3 to 
induce an increase in the mature SMC pool and extracellular matrix deposition in the grafts 
when compared to control, we would speculate that the functionality and regeneration of the 
Dkk3-TEVGs would be at least similar to or better than the control-TEVGs. Nevertheless, 
further investigation is required to clarify this issue. 
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The precise origin of the Sca-1+ progenitor cells present in the Dkk3-TEVGs is still under 
investigation. Published studies indicate that the Sca1+ cells could originate from two 
sources, which are local resident and circulating progenitor cells8, 13, 41, 61, 62. For the current 
study, we speculate that both sources may contribute to the pool of Sca-1+ cells in the Dkk3-
TEVGs. We have shown in another study that a large number of cells infiltrating our TEVGs 
derives from the surrounding native tissue, as the infiltrating cells migrate from the outer 
layers of the TEVGs to the inner layers3. The use of Sca-1 knock-in inducible Cre animal 
models would help us clarify the fate and progeny of Sca-1+ VPCs. Rigorous lineage-tracing 
methodology may further elucidate the role of Dkk3 in the migration, proliferation and 
differentiation of Sca-1+ progenitor cells.  
In summary, our work shows for the first time that Dkk3 plays a chemotactic role in vascular 
progenitor cells through binding to the chemokine receptor CXCR7 and activating relevant 
downstream molecular mechanisms. Furthermore, the in vivo chemotactic property of Dkk3 
as well as the potential to promote in vivo vascular graft arterialisation have been verified in 
an animal model. Our findings herein presented provide evidence of the potential of Dkk3 
and its receptor CXCR7 as targets for vascular drug targeted therapy strategies and 
regenerative medicine.  
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Figure Legends 
 
Figure 1. Dkk3 induces migration of resident Sca-1+ VPCs in vitro and ex vivo. 
(a) Representative images of migrated Sca-1+ cells induced by increasing concentration of 
either Dkk3 or Sdf-1α (0, 10, 25, 50 and 100 ng/mL), in a transwell migration assay 
performed during 12 hours (20x magnification). (b, c) Quantification of the transwell assay 
with Dkk3 and Sdf-1α stimulation, respectively (n=5). (d) Representative images of migrated 
Sca-1+ cells, 16 hours after the initiation of wound healing assay, at increasing 
concentration of either Dkk3 or Sdf-1α (0, 10, 25, 50 and 100 ng/mL). Blue solid lines denote 
the margins of the wound (20x magnification). (e, f) Quantification of cells that migrated to 
close the wounded area in response to Dkk3 and Sdf-1α, respectively (n=5). Both migration 
assays showed that Dkk3 induces Sca-1+ cell migration and that the chemotactic effect of 
Dkk3 is similar to the observed with Sdf-1α stimulation. (g) Representative images of cell 
outgrowth from aortic rings from wild type and ApoE-/- mice induced by either Dkk3 (25 
ng/mL) or Sdf-1α (25 ng/mL) treatment. (h, i) Quantitative analysis of cell outgrowth from 
wild type and ApoE-/- mice aortic rings, respectively (n=4). Dkk3 induces cell outgrowth from 
ApoE-/- aortic rings, whereas Sdf-1α induces cell outgrowth from both wild type and ApoE-/- 
explants. (j) Representative immunofluorescence images of aortic rings from transgenic Sca-
1-GFP ApoE-/- mice treated with either Dkk3 (25 ng/mL) or Sdf-1α (25 ng/mL). DAPI was 
included to counterstain the nuclei (20x magnification). (k) Quantification of the number of 
Sca-1+-GFP cells that outgrew from the aortic rings (n=3). (l) Quantification of the 
percentage of Sca-1+-GFP cells against the total number of cells present in the outgrowth 
(n=3). Dkk3 promotes Sca-1+ cell outgrowth from ApoE-/- aortic rings in a similar manner as 
Sdf-1α does. The data are expressed as the mean±s.e.m. of 5 independent experiments for 
the in vitro migration assays (a-f) and of 3 to 4 independent experiments for the ex vivo 
migration assays (g-l). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 compared with control 
group (0 ng/mL) (One-way ANOVA followed by Bonferroni’s post-hoc test). 
 
Figure 2. CXCR7 is involved in Dkk3-driven migration of Sca-1+ cells. 
(a) Representative flow cytometry dot plots of CXCR4 and CXCR7 surface expression in 
Sca-1+ cells. (b) Quantification of Sca-1+/CXCR4+, Sca-1+/CXCR7+ and Sca-
1+/CXCR7+/CXCR4+ cells by flow cytometry analysis (n=3, one-way ANOVA followed by 
Bonferroni’s post-hoc test). CXCR7 is expressed in 78% (77.9%±6.2%) of Sca-1+ cells 
whereas CXCR4 is expressed in only 1% (0.9%±0.2) of the cells. (c) Western blot analysis 
of CXCR4 and CXCR7 expression in murine endothelial cells (EC), Sca-1+ cells (VPC) and 
smooth muscle cells (SMC). CXCR7 is highly expressed in Sca-1+ cells and SMCs. CXCR4 
expression in Sca-1+ cells is low in comparison to its expression in ECs and SMCs. (d). 
Quantitative RT-qPCR analysis of CXCR7 expression in Sca-1+ cells transfected with siRNA 
targeting CXCR7. Expression levels were normalized against GAPDH (n=5, two-tailed 
Student’s t-test). (e) Western blot analysis of CXCR7 knockdown in Sca-1+ cells transfected 
with CXCR7 siRNA. (f, h) Representative images of transwell migration assay of Sca-1+ 
cells transfected with CXCR7 siRNA in response to Dkk3 (25 ng/mL) and Sdf-1α (25 ng/mL) 
treatment, respectively. (g, i) Quantitative analysis of the migrated cells in response to Dkk3 
or Sdf-1α treatment (n=4, Two-way ANOVA followed by Bonferroni’s test). CXCR7 
knockdown in Sca-1-VPCs supresses Dkk3-mediated migration, similarly to the observed 
with Sdf-1α treatment. The data are expressed as the mean±s.e.m. of 3 to 5 independent 
experiments. **P<0.01, ***P<0.001, ****P<0.0001, compared with control group (0 ng/mL). 
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Figure 3. CXCR7 is a high-affinity binding receptor of Dkk3. 
(a) Co-Immunoprecipitation of Dkk3 with CXCR7. Dkk3 co-immunoprecipitates with CXCR7 
from Sca-1+ cells. (b) Immunoblotting of the receptors pulled-down from Dkk3-His tagged, 
using Nickel magnetic beads. Sca-1+ cells were treated with Dkk3-His tagged. CXCR7, but 
not CXCR4, is pulled-down with Dkk3-His. (c) Quantitative RT-PCR analysis of CXCR7 
mRNA expression in HEK 293T cells transfected with CXCR7 expression plasmid. 
Expression levels were normalized against GAPDH (n=4, two-tailed unpaired Student’s t-
test). (d) Western blot analysis of CXCR7 overexpression in HEK 293T cells transfected with 
CXCR7 expression plasmid. (e, f) Representative binding curves and respective Scatchard 
analysis of Sdf-1α–AP binding to CXCR4 or CXCR7 overexpressed in HEK 293T cells and 
of Dkk3–AP binding to CXCR7, CXCR4, Kremen1 or Kremen2 overexpressed in HEK 293T 
cells, respectively. The dissociation constants (Kd) are represented for each receptor (n=3). 
Dkk3-AP does not bind to CXCR4, Kremen1 and Kremen2, but it does bind with high affinity 
to CXCR7, as represented by the characteristic hyperbolic binding curve. CXCR7 is also a 
high-affinity binding receptor of Sdf-1α, alongside its cognate receptor CXCR4. AP alone 
does not bind to CXCR7, as depicted in blue. (g, i) Representative images of transwell 
migration assay of HEK 293T cells overexpressing CXCR7 in response to Dkk3 and Sdf-1α 
stimulation, respectively. (h, j) Quantitative analysis of the transwell migration assays. Dkk3 
induces migration of CXCR7 overexpressing HEK 293T cells, analogously to Sdf-1α. (n=5, 
Two-way ANOVA followed by Bonferroni’s post-hoc test). The data are expressed as the 
mean±s.e.m. of 3 to 5 independent experiments. *P<0.05, **P<0.01, compared with control 
group.  
 
Figure 4. ERK1/2 and PI3K/AKT signalling pathways act downstream of Sca-1+ cell 
migration mediated by Dkk3 binding to CXCR7. 
(a, b) Western blot analysis of phosphorylated and total ERK1/2 and AKT proteins in Sca-1+ 
cells stimulated with Dkk3 at the indicated time points. ERK1/2 and AKT phosphorylation 
increases in response to Dkk3. (c, d) Western blot analysis of Dkk3-induced ERK1/2 and 
AKT activation in Sca-1+ cells after CXCR7 knockdown by siRNA transfection. 
Downregulation of CXCR7 abolishes Dkk3-triggered phosphorylation of ERK1/2 and AKT. 
(e, f) Western blot analysis of ERK1/2 and AKT activation in Sca-1+ cells stimulated with 
Dkk3 for 5 minutes and pre-treated with, respectively, PD98059 and LY294002. ERK1/2 and 
AKT activation is supressed upon treatment with the inhibitors. (g, h, i) Quantification of 
Dkk3-driven Sca-1+ cell migration upon treatment with, respectively, PD98059 (10 µM, n=5), 
LY294002 (10 µM, n=3) and AKT inhibitor (2.5 µM, n=4). Dkk3-driven cell migration is 
abrogated in response to all inhibitors. Western blot images are representative of three 
independent experiments. The data are expressed as the mean±s.e.m. of 3 or 5 
independent experiments. *P<0.05, **P<0.01, ***P<0.001, compared with control group (0 
ng/mL) (Two-way ANOVA followed by Bonferroni’s post-hoc test). 
 
Figure 5: Rac1 and RhoA GTPases activation is required for Sca-1+ cell migration 
induced by Dkk3 binding to CXCR7. 
(a, e) Quantification of Rac1-GTP and RhoA-GTP in Sca-1+ cells treated with Dkk3 at the 
time points indicated. Dkk3 induces Rac1 and RhoA activation. (b, f) Quantification of Dkk3-
triggered activation of Rac1 and RhoA after CXCR7 knockdown by siRNA transfection. 
Downregulation of CXCR7 abolishes Dkk3-triggered activation of Rac1 and RhoA (n=3). (c) 
Quantification of Dkk3-induced Rac1 activation upon treatment with NSC23766 (10 µM, 
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n=3). Dkk3-induced increase of Rac1-GTP level at 10 and 15 minutes is repressed by the 
inhibitor NSC23766. (d) Quantification of Dkk3-driven Sca-1+ cell migration upon NSC23766 
treatment. NSC23766 inhibitor abolishes Sca-1+ cell migration promoted by Dkk3 treatment 
(n=4). (g) Quantification of Dkk3-induced RhoA activation upon Rhosin (10 µM, n=3) 
treatment. Dkk3-induced increase of RhoA-GTP level is repressed by the inhibitor Rhosin, at 
the time points indicated. (h) Quantification of Dkk3-driven Sca-1+ cell migration upon 
Rhosin treatment (n=3). Rhosin abolishes Sca-1+ cell migration promoted by Dkk3 
treatment. (i) Western blot analysis of MLC phosphorylation in response to Dkk3 stimulation. 
MLC phosphorylation is induced by Dkk3 at the time points indicated. (j) Western blot 
analysis of Dkk3-driven MLC phosphorylation upon pre-treatment with Rhosin or Y27632, at 
the time point indicated. Dkk3-induced MLC phosphorylation is repressed in response to the 
inhibitors. (k) Quantification of Dkk3-driven Sca-1+ cell migration upon Y27632 treatment. 
Sca-1+ cell migration promoted by Dkk3 treatment is inhibited by Y27632 (5 µM, n=4) 
treatment. The western blot images are representative of 3 independent experiments. The 
data are expressed as the mean±s.e.m. of 3 to 4 independent experiments. *P<0.05, 
**P<0.01, ****P<0.0001, compared with control group (0 ng/mL) (One-way ANOVA for a and 
e and Two-way ANOVA for b, c, d, f, g, h and k, followed by Bonferroni’s post-hoc test). 
 
Figure 6. Delivery of Dkk3 in tissue engineered vessel grafts (TEVGs) enhances 
vascular regeneration. 
Dkk3-loaded TEVGs were implanted into rats to replace the abdominal artery and then 
harvested at 2 weeks, 1 and 3 months post-implantation. (a) H&E staining on cross-sections 
of control and Dkk3-loaded TEVGs 3 months post-implantation. Both grafts are fully 
cellularized and no evident intimal hyperplasia is observed. (b) Quantification of the inner 
diameter of the TEVGs at 2 weeks, 1 and 3 months. The inner diameters of the grafts remain 
unchanged up to three months post-implantation. (c). Representative images of the luminal 
surface of the explanted TEVGs, 3 months post-implantation, obtained by scanning 
electronic microscopy. Three locations were selected continuously from the anastomotic 
sites to the middle of the grafts and the respective magnified images are shown. The surface 
of Dkk3-TEVGs throughout the graft is more continuous and homogeneous in comparison 
with the control group. (d) Representative immunofluorescence images of control- and Dkk3-
TEVGs showing SMC recruitment by staining the sections with anti-α-SMA and anti-SMMHC 
antibodies. DAPI was used to counterstain the nuclei. (e, f, g) Quantification of smooth 
muscle regeneration by determination of the total area of α-SMA and of SM-MHC positive 
cells in the luminal region (delineated by the white dashed lines) at different time points. 2 
weeks after implantation, Dkk3-loaded TEVGs display an increase of α-SMA+ cells, 
compared to control. Over time, the smooth muscle becomes more mature in Dkk3-TEVGs 
than in control grafts, as the area of SM-MHC+ cells is also increased. The images are 
representative of 4 grafts for each group. The data are expressed as the mean±s.e.m. of 4 
independent experiments. *P<0.05, compared with control group (Two-way ANOVA followed 
by Bonferroni’s post-hoc test for b, e, f and g). 
 
Figure 7. Dkk3 increases Sca1+ progenitor migration and smooth muscle 
differentiation. 
Schematic illustration of the three types of TEVGs. Control TEVGs composed of PCL and 
collagen fibers; Dkk3-TEVG composed of PCL and Dkk3-collagen fibers; Dkk3-CXCR7 ab-
TEVG composed of PCL, Dkk3-collagen and CXCR7 antibody-collagen fibers. (b) 
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Representative immunofluorescence images of the cross-sections of TEVGs displaying 
Sca1+ progenitor cells recruitment into the grafts detected with anti-Sca-1 antibody (green), 
at the time points indicated. (c) Quantification of Sca-1+ progenitor cell infiltration into the 
three types of TEVGs. DKK3 delivery significantly promotes the infiltration of Sca1+ 
progenitor cells into the grafts. The incorporation of CXCR7 antibody in the grafts markedly 
inhibits infiltration of Sca1+ progenitor cells into the grafts. (d) Representative 
immunofluorescence images of the cross-sections of TEVGs exhibiting double 
immunostaining with anti-α-SMA (green) and anti-Sca-1 (red) antibodies, at the time points 
indicated. The increased contribution of double positive cells (Sca-1+/α-SMA+) to the 
smooth muscle regeneration in Dkk3-TEVGs, compared to control group, seems to decrease 
in Dkk3-CXCR7 ab-TEVGs. DAPI was included to counterstain the nuclei. The data 
presented are representative images of four grafts for each group and expressed as the 
mean±s.e.m. of 4 independent experiments. **P<0.01, compared with control group (Two-
way ANOVA, followed by Bonferroni’s post-hoc test). 
 
Figure 8. Schematic illustration of Dkk3/CXCR7 mediated Sca1+ progenitor migration. 
The figure depicts the molecular mechanism involved in Sca-1+ progenitor migration 
induced by Dkk3 binding to CXCR7. Dkk3 present in the cell environment binds to CXCR7 
expressed on the surface of Sca-1+ progenitors. Upon CXCR7 activation, ERK1/2 signalling 
pathway is activated. Phosphorylated ERK1/2 either activates Rac1 or directly modulates 
cytoskeleton rearrangement to promote cell migration. Rac1 activation also results from 
Dkk3 binding to CXCR7, which in turn directly regulates cell migration and/or stimulates ERK 
phosphorylation. Rac1 and ERK1/2 seem to work in a feedback manner. The Dkk3/CXCR7 
axis promotes AKT phosphorylation via PI3K, which leads to cytoskeleton rearrangement. 
RhoA activation level is increased in response to Dkk3 binding to CXCR7, leading to MLC 
phosphorylation either directly or via ROCK activation. MLC activation results in actomyosin 
contraction required for cell migration. 
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NOVELTY AND SIGNIFICANCE 
 
What Is Known? 
 
*Dickkopf-3 (Dkk3) is involved in vascular remodelling, e.g. atherosclerosis, vascular injury-
induced stenosis and plaque stability. 
 
*Tissue-engineered vessel grafts constitute an effective alternative to the limited availability 
of autografts used for blood vessel replacement. 
*Vascular progenitor cells play an active role in vascular remodelling and regeneration. 
 
What New Information Does This Article Contribute? 
 
*Dkk3 can specifically bind to a chemokine receptor CXCR7. 
 
*Dkk3-CXCR7 axis is crucial for vascular stem cell migration. 
 
*Tissue-engineered vessel grafts containing Dkk3 showed better cellularization and 
regeneration. 
 
Vascular resident stem/progenitor cells have an ability to regenerate damaged tissues. A 
cytokine-like protein Dkk3 is able to bind to a chemokine receptor CXCR7 resulting cell 
signalling and cytoskeleton rearrangement, which led to stem cell migration. When Dkk3 was 
used to generate a degradable vessel grafts, it has a role to attract stem cells into the grafts 
in animal models. This tissue-engineered grafts displayed a better regeneration and 
potentially have a longer patency in vivo. Thus, Dkk3 induces vessel graft regeneration by 
recruiting host vascular stem cells via CXCR7 activation. 
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